IDENTIFY研究:疑似泌尿系肿瘤转诊患者中泌尿系肿瘤患病率的多中心观察研究
调整年龄、血尿类型、性别、吸烟、医院和国家后,总体癌症患病率28.2%,膀胱癌24.7%最常见,可见血尿是最强预测因素。
要点
- 疑似泌尿系肿瘤转诊患者中调整后总体癌症患病率为28.2%。
- 膀胱癌患病率24.7%,为最常见肿瘤类型。
- 可见血尿为泌尿系肿瘤最强预测因素(OR 3.47)。
核心结论
- 疑似泌尿系肿瘤转诊患者中调整后总体癌症患病率为28.2%,膀胱癌最常见。
- 可见血尿是泌尿系肿瘤最强预测因素,吸烟、男性、年龄亦为独立风险标志。
研究设计与样本
- 排除已知或既往泌尿系恶性肿瘤患者,采用多因素混合效应logistic回归调整患病率。
主要发现
- 总体调整癌症患病率28.2%(95%CI 22.3-34.1),膀胱癌24.7%(95%CI 19.1-30.2)。
- 上尿路尿路上皮癌患病率1.14%(95%CI 0.77-1.52),肾癌1.05%(95%CI 0.80-1.29),前列腺癌1.75%(95%CI 1.32-2.18)。
- 所有癌症模型中年龄OR 1.04(95%CI 1.03-1.05;P<0.001),可见血尿OR 3.47(95%CI 2.90-4.15;P<0.001),男性OR 1.30(95%CI 1.14-1.50;P<0.001),吸烟OR 2.70(95%CI 2.30-3.18;P<0.001)。
临床怎么用
- 对疑似泌尿系肿瘤转诊患者应结合年龄、血尿类型、性别和吸烟史评估癌症风险。
- 可见血尿患者应优先安排进一步检查以排除泌尿系肿瘤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract urothelial cancer [UTUC] and renal cancer) in patients referred to secondary care with haematuria, adjusted for established patient risk markers and geographical variation. PATIENTS AND METHODS: This was an international multicentre prospective observational study. We included patients aged ≥16 years, referred to secondary care with suspected urinary tract cancer. Patients with a known or previous urological malignancy were excluded. We estimated the prevalence of bladder cancer, UTUC, renal cancer and prostate cancer; stratified by age, type of haematuria, sex, and smoking. We used a multivariable mixed-effects logistic regression to adjust cancer prevalence for age, type of haematuria, sex, smoking, hospitals, and countries. RESULTS: Of the 11 059 patients assessed for eligibility, 10 896 were included from 110 hospitals across 26 countries. The overall adjusted cancer prevalence (n = 2257) was 28.2% (95% confidence interval [CI] 22.3-34.1), bladder cancer (n = 1951) 24.7% (95% CI 19.1-30.2), UTUC (n = 128) 1.14% (95% CI 0.77-1.52), renal cancer (n = 107) 1.05% (95% CI 0.80-1.29), and prostate cancer (n = 124) 1.75% (95% CI 1.32-2.18). The odds ratios for patient risk markers in the model for all cancers were: age 1.04 (95% CI 1.03-1.05; P < 0.001), visible haematuria 3.47 (95% CI 2.90-4.15; P < 0.001), male sex 1.30 (95% CI 1.14-1.50; P < 0.001), and smoking 2.70 (95% CI 2.30-3.18; P < 0.001). CONCLUSIONS: A better understanding of cancer prevalence across an international population is required to inform clinical guidelines. We are the first to report urinary tract cancer prevalence across an international population in patients referred to secondary care, adjusted for patient risk markers and geographical variation. Bladder cancer was the most prevalent disease. Visible haematuria was the strongest predictor for urinary tract cancer.
引用
- Khadhouri S, Gallagher KM, MacKenzie KR, et al. The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer - a multicentre observational study. BJU Int. 2021. PMID: 33991045. doi:10.1111/bju.15483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。